



RECEIVED
JAN 03 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS,
WASHINGTON, D.C. 20231, ON DECEMBER 19, 2002

A. J. A.
AGENT/ATTORNEY FOR APPLICANT

DEC. 19, 2002

DATE

Attorney Docket No. B2368C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hindley, et al.

Application No.: 08/458, 033

Filed: June 1, 1995

For: Novel Compounds

Group No.: 1626

Examiner: Robert Gerstl

Commissioner for Patents

Washington, DC 20231

RESPONSE TO FINAL OFFICE ACTION
SUBMITTED PURSUANT TO 37 CFR 1.129(a)

This is responsive to the final Office Action mailed on May 3, 2002, setting a three (3) month period for response (hereinafter also referred to as the "Office Action"). A Notice of Appeal and a Petition to extend the time for response for a period of three (3) months was filed on October 29, 2002. Applicants now respectfully request entry and consideration of the following amendment being submitted in accordance with 37 CFR 1.129(a).

IN THE CLAIMS:

- Please cancel claims 1-12 without prejudice to or disclaimer of their subject matter.
- Please add the following new claims:

17. (new) A method for the treatment of type II diabetes in a human or non-human mammal which comprises administering an effective, non-toxic amount of a compound which is selected from 5-(4-[2-(N-methyl-N-(2-